David J. Maloney

Noble Life Sciences, Inc. provides in vitro and in vivo preclinical drug development services. It specializes in personalized medicine and biomarker research and preclinical drug development. The company was founded by Kenneth C. Carter in 2010 and is headquartered in Sykesville, MD.

Capillary Biomedical, Inc. develops medical devices for diabetes management. The company was founded by Jeffrey Joseph and Paul Strasma and is headquartered in Irvine, CA.

Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Part of Valiant Co., Ltd., BIO 101, Inc. is a company that develops DNA and RNA purification kits and laboratory tools. The company is based in Carlsbad, CA. BIO 101 was acquired by Quantum Biotechnologies USA on April 05, 2000.

Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina.

Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ.

AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC.

National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD.

North Carolina Biosciences Organization is non-profit organization, which focuses on legislative monitoring and lobbying activities at the state and federal level. The company was founded in 1994 and is headquartered in Durham, NC.

Endeavour Vision SA (EV) is an independent venture capital firm headquartered in Geneva. EV traces their origins back to 1989 through the convergence of the Vision Capital European team and the Swiss VC firm, Endeavour. EV was co-founded in 2000 by Sven Lingjaerde and Damien Tappy. The firm specializes in providing funding for entrepreneurs in life sciences, biotech, medtech, cleantech and information technology. EV operates in close cooperation with Genevest, an independent investment vehicle which has reached the divestment stage. Their investors in the funds they advise are industrial corporations, family offices, global institutional investors and business leaders in the technology and investment industry.

Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts.

Navigen, Inc. operates as a drug discovery and development company. The company was founded by Hunter Jackson and is headquartered in Salt Lake City, UT.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA.

Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California.

DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY.

Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA.

The Sophocles Group LLC provides investment services. The private company is based in Princeton.

JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts.

Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA.

I2o Therapeutics, Inc. develops injection pills for biological therapies. It offers revolutionary oral delivery platform such as high bioavailability, low cost of goods, superior drug loading, injection free delivery, readily scalable, and compatible with diverse drug types. The company was founded by Samir Mitragotri, Ravi Srinivasan, Kelly Ibsen, and Tyler Brown in 2019 and is headquartered in Allston, MA.

Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA.

DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France.

Tech Health Experts provides technical support services.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.